Clinical Trials
4 trialsNCT01222286 2026-05-14
KIRMONO
Innate Pharma
Phase 2 Completed
NCT02316106 2026-04-23
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Janssen Research & Development, LLC
Phase 2 Completed
NCT03301220 2026-04-13
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT01441973 2018-01-23
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
Bristol-Myers Squibb
Phase 2 Completed